CIMB has an “add" recommendation on GI Dynamics and a $1.04 target price.
In a broker’s note, CIMB says “GID continues to advance EndoBarrier commercialisation efforts, with 60 centres of excellence (COE) now servicing patients.
Loading...
Will Willitts is a Sydney-based desk editor; previously posted in Washington, Frankfurt, Mexico City and Ottawa, he has worked with Reuters, Bloomberg and Dow Jones. Connect with Will on Twitter. Email Will at wwillitts@afr.com
